Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2008
Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study.
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 79 citations in OpenAlex.
- NCCN Task Force Report: Bone Health in Cancer Care.Journal of the National Comprehensive Cancer Network : JNCCN · 2009Guideline
- Trial
- The adverse effect of anticancer drug toremifene on vascular smooth muscle cells is an important aspect of its tumor growth inhibition.Journal of cancer research and clinical oncology · 2023Article
- UPDATE - Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2022Article
- Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2021Article
- Protocol for a phase III RCT and economic analysis of two exercise delivery methods in men with PC on ADT.BMC cancer · 2018Article
- Estrogen and Androgen Blockade for Advanced Prostate Cancer in the Era of Precision Medicine.Cancers · 2018Review
- Effect of androgen deprivation therapy on arterial stiffness and serum lipid profile changes in patients with prostate cancer: a prospective study of initial 6-month follow-up.International journal of clinical oncology · 2016Observational
- Management of endocrine disease: Secondary osteoporosis: pathophysiology and management.European journal of endocrinology · 2015Review
- The use of dietary supplements to alleviate androgen deprivation therapy side effects during prostate cancer treatment.Nutrients · 2014Review
- Androgen deprivation therapy for prostate cancer: long-term safety and patient outcomes.Patient related outcome measures · 2014Review
- Selective estrogen receptor modulators for BPH: new factors on the ground.Prostate cancer and prostatic diseases · 2013Review
- Fasting blood glucose and lipid profile alterations following twelve-month androgen deprivation therapy in men with prostate cancer.TheScientificWorldJournal · 2012Article
- Androgen deprivation therapy toxicity and management for men receiving radiation therapy.Prostate cancer · 2012Article
- Cardiotoxicity of molecularly targeted agents.Current cardiology reviews · 2011Review
- Use of testosterone replacement therapy in patients with prostate cancer.Current urology reports · 2011Review
- Estrogen action and prostate cancer.Expert review of endocrinology & metabolism · 2011Article
- Article
- Changes in blood glucose and cholesterol levels due to androgen deprivation therapy in men with non-metastatic prostate cancer.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2011Article
- An update on the changing indications for androgen deprivation therapy for prostate cancer.Prostate cancer · 2011Article
Corrections and comments
- Commented on by
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
purposeAndrogen-deprivation therapy (ADT) is associated with greater risk of incident coronary heart disease and hospital admission for myocardial infarction; treatment-related increases in serum lipids may contribute to greater cardiovascular disease risk. We evaluated the effects of toremifene, a selective estrogen-receptor modulator, on fasting serum lipid levels in men receiving ADT for prostate cancer. PATIENTS AND
methodsIn an ongoing, multicenter, double-blind, placebo-controlled phase III fracture-prevention study, 1,389 men receiving ADT for prostate cancer were randomly assigned to receive toremifene (80 mg/d) or placebo. In this interim analysis of 188 patients, changes in fasting serum lipids from baseline to month 12 were compared between the placebo and toremifene groups.
resultsChanges in serum lipids differed significantly between the groups. Mean (+/- SE) total cholesterol decreased by 1.0% +/- 1.7% from baseline to month 12 in the placebo group and decreased by 8.1% +/- 1.4% in the toremifene group (P = .001 for between group comparison). Low-density lipoprotein (LDL) cholesterol increased by 0.8% +/- 2.5% in the placebo group and decreased by 8.2% +/- 2.5% in the toremifene group (P = .003). In contrast, high-density lipoprotein (HDL) cholesterol decreased by 4.9% +/- 1.2% in the placebo group and increased by 0.5% +/- 2.2% in the toremifene group (P = .018). Triglycerides increased by 6.9% +/- 4.2% in the placebo group and decreased by 13.2% +/- 3.6% in the toremifene group (P = .003).
conclusionToremifene significantly decreased total cholesterol, LDL cholesterol, and triglycerides, and increased HDL cholesterol in men receiving ADT for prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.